Plecanatide: Completed Phase IIb/III enrollment

Synergy completed enrollment of about 880 patients in a double-blind, placebo-controlled, U.S. Phase IIb/III trial (SP304-20210) evaluating 0.3, 1 or 3 mg oral plecanatide once daily for 12 weeks. In ...